Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)

v3.22.1
Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Income Statement [Abstract]    
Research and development $ 1,546 $ 1,009 [1]
[1] The Company reclassified $1,009 research and development expenses, reported in previous period in general and development expense, to conform to the current period presentation.